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Proline/arginine-rich end leucine-rich repeat protein (PRELP) is a collagen-binding proteoglycan highly
expressed in the developing bones. Recent studies indicated that PRELP could inhibit osteoclastogenesis
as a NF-kB inhibitor. However, its role during osteoblast differentiation is still unclear. In this study, we
conﬁrmed that the expression of PRELP increased with the osteogenesis induction of preosteoblastic
MC3T3-E1 cells. Down-regulation of PRELP expression by shRNA reduced ALP activity, mineralization
and expression of osteogenic marker gene Runx2. Our microarray analysis data suggested that b-catenin
may act as a hub gene in the PRELP-mediated gene network. We validated furtherly that PRELP
knockdown could inhibit the level of connexin43, a key regulator of osteoblast differentiation by
affecting b-catenin protein expression, and its nuclear translocation in MC3T3-E1 preosteoblasts.
Therefore, this study established a new role of PRELP in modulating b-catenin/connexin43 pathway and
osteoblast differentiation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Identiﬁcation of novel mediator regulating in osteogenesis is of
great signiﬁcance in understanding the mechanism of bone for-
mation process under physiological and pathological conditions [1].
Proline/arginine-rich end leucine-rich repeat protein (PRELP) is a
small leucine-rich proteoglycan (SLRP), which binds collagen to
basement membranes or cartilage as a matrix protein [2,3]. It has
been demonstrated that PRELP was highly expressed in developing
bones, and its mutation was also involved in the pathogenesis of
HutchinsoneGilford progeria, which was characterized, among
other symptoms, by bone deformities and osteoporosis [4,5]. These
evidences supported that PRELP was likely to play a physiological
role in the control of bone remodeling and homeostasis.Sciences, University of Jinan-
ong, China.
work.
Inc. This is an open access article uRecently, Rucci et al. found that overexpression of PRELP could
impair osteoclastogenesis in vitro and in vivo, and the inhibitory
effect was depended on its glycosaminoglycan-binding domain
which acted as a NF-kB inhibitor [6,7]. In a previous study, we
performed a time-course microarray analysis on the gene expres-
sion during osteogenic differentiation of mesenchymal stem cells,
and found that PRELP level increased in osteogenesis in a time
course manner (unpublished data). This ﬁnding suggested that
PRELP may play an important role in modulating osteoblast dif-
ferentiation. In this study, we furtherly explored the role of PRELP in
preosteoblastic MC3T3-E1 cells during osteogenesis differentiation,
and suggested that PRELP may act as a novel regulator of osteo-
blastic differentiation through b-catenin pathway.
2. Materials and methods
2.1. Cell culture and osteogenesis induction
MC3T3-E1 mouse calvarial pre-osteoblasts were acquired from
the Cell Bank of Type Culture Collection of the Chinese Academy ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Gibco, CA, USA) with 10% (v/v) fetal bovine serum (Gibco, CA,
USA) and 1% penicillin-streptomycin at 37 C in a humidiﬁed at-
mosphere containing 5% CO2. To induce osteogenesis, subconﬂuent
MC3T3-E1 cells were cultured in DMEM medium (Gibco, CA, USA)
supplemented with a cocktail of L-ascorbic acid, dexamethasone
and b-glycerophosphoric acid (MK430, Takara Bio, Shiga, Japan)
every three days.
2.2. Establishment of MC3T3-E1 sublines with stable PRELP
knockdown
To deﬁne the role of PRELP in osteoblast differentiation, we
established two MC3T3-E1 subline cells stably expressing PRELP
short hairpin RNA (shRNA) using a Lentivirus vector (pGLVH1/
GFP þ Puro, GenePharma, Shanghai, China). MC3T3-E1 cells were
plated at a density of 1  104 cells/cm2 in 24-well plates, after the
cells reached 50e70% conﬂuence, two PRELP shRNA vectors or one
control vector were infected, and the medium were replaced after
24 h. Then stable MC3T3-E1 cells were selected with puromycin
(2 mg/ml puromycin) for 14 days.
2.3. In vitro osteogenic assay
Alkaline phosphatase (ALP) activity of cell lysates at 7 d of
osteogenesis induction was determined using an Alkaline Phos-
phatase Opt kit (GenMed Scientiﬁcs I nc, USA) according to the
manufacturer's instruction. Cells were ﬁxed with ice-cold 70%
ethanol and stained with an Alizarin red kit (GenMed Scientiﬁcs I
nc, USA) according to the manufacturer's instruction in order to
detect mineralization after 21 d of differentiation.
2.4. Quantitative real-time PCR (qRT-PCR)
Total RNA extracted from the cultured cells was used tomeasure
mRNA expression levels of the genes under study. The sequences of
the primers used in this study are listed in Table 1 qRT-PCR was
performed (LightCycler 480 thermocycler, Roche Applied Science,
Mannheim, Germany) using a SYBR Green qPCR Kit (Toyobo, Osaka,
Japan).
2.5. Western-blot
Cytoplasmic and nuclear proteins of cells under study were
extracted by the Nuclear and Cytoplasmic Protein Extraction Kit
(Beyotime, China). Equal amounts (30 mg) of lysate were subjected
to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred to a polyvinylidene ﬂuoride (PVDF) membrane.
After blocking, membrane was incubated overnight using anti-
bodies against PRELP (1:1000, Santa Cruz, CA, USA), b-catenin
(1:1000, Beyotime, China), connexin43 (1:1000, Cell Signaling
Technology, MA, USA), LaminB1 (1:1000, Proteintech Group,Table 1
List of primers for qRT-PCR.
Gene Sequence
PRELP forward 50-CCC GAA TCC ATT ACC TTT ACT T-30
reverse 50-CAT CCC AGA GCT GAA CG-30
RUNX2 forward 50-AAG TGC GGT GCA AAC TTT CT-30
reverse 50-TCT CGG TGG CTG GTA GTG A-30
CX43 forward 50-GGG GAA GGA TGA AGG AGG GA-30
reverse 50-TGC GGT TGA TGT AGT AAC AGT CGT-30
GAPDH forward 50-CAT CCC AGA GCT GAA CG-30
reverse 50-CTG GTC CTC AGT GTA GCC-30Chicago, IL, USA), b-actin (1:3000, Beyotime, China). The blots were
developed by using ECL Plus (Millipore, Billerica, MA, USA) and
exposed to X-ray ﬁlm.2.6. Immunoﬂuorescence
Cells were ﬁxed with 4% paraformaldehyde for 10 min at room
temperature and washed with PBS. After blocking, cells were
stained with the primary antibody against b-catenin (1:50, Beyo-
time, China). Then the primary antibodywere visualizedwith Alexa
Fluor® 594-conjugated goat anti-rabbit IgG. Cell nuclei were
stained with DAPI. Fluorescence images were taken using a ﬂuo-
rescence microscope (Leica Microsystems, Germany).2.7. Gene expression microarray analysis
Genome-wide expression proﬁling analysis was performed us-
ing Affymetrix GeneChip Mouse Gene 1.0ST Array to identify PRELP
related genes and signal pathways according to the manufacturer's
instruction. Gene expression proﬁle raw data were processed by
RMA method. Differently expressed genes between PRELP shRNA
and control groups were analyzed by the Q value method [8]. Q
value was set as 0.05, and fold as 2. Proteineprotein interactions
(PPIs) were extracted from the STRING (Search Tool for the Retrieval
of Interacting Genes) database [9].2.8. Statistics
Data are shown as the mean ± S.D., and the statistical signiﬁ-
cance between groups was analyzed using the Student's t-test.
p < 0.05 was considered statistically signiﬁcant.3. Results
3.1. PRELP expression during osteoblasts differentiation
To examine the changes in PRELP expression during osteoblast
differentiation, MC3T3-E1 cells were cultured for 21 days in dif-
ferentiation medium. Osteoblast differentiation was conﬁrmed by
measuring the expression differentiation markers ALP and RUNX2,
ALP activity and mineralized nodule formation. As seen in Fig. 1A
and B, expression of PRELP in differentiated MC3T3-E1 cells at all
stages were higher than in the undifferentiated cells by both qRT-
PCR and Western-blot analysis. qRT-PCR results also indicated
that PRELP expression gradually increased throughout the differ-
entiation process, which was consistent with our previous
expression microarray ﬁnding.3.2. PRELP knockdown inhibits osteoblast differentiation
We established two sublines of MC3T3-E1 cells stably express-
ing shRNA which signiﬁcantly knocked down PRELP mRNA and
protein levels as compared with controls (Fig. 2A and B). qRT-PCR
veriﬁed that PRELP knockdown reduced mRNA expression of
osteoblast differentiation marker RUNX2 after 12 d of induction
(Fig. 2C). In vitro osteogenic assay results also indicated that PRELP
knockdown could signiﬁcantly decrease ALP staining and miner-
alized nodule formation in MC3T3 cells compared with the mock
shRNA controls (Fig. 2D and E). Above ﬁndings suggested that
PRELP did inhibit osteoblast differentiation at both early and late
stages.
Fig. 1. Expression pattern of PRELP during osteogenesis differentiation in MC3T3-E1 cells. (A) qRT-PCR results indicated that PRELP expression gradually increased throughout the
differentiation process; (B) Western-blot results conﬁrmed that differentiated MC3T3-E1 cells at all stages had a higher PRELP expression than the undifferentiated cells.
Fig. 2. Effect of PRELP knockdown on osteoblasts differentiation in MC3T3-E1 cells. (AeB) mRNA and protein levels were signiﬁcantly knocked down by shRNA; (C) PRELP
knockdown reduced mRNA expression of osteoblast differentiation marker RUNX2; (DeE) In vitro osteogenic assay results indicated that PRELP knockdown can signiﬁcantly
decrease ALP staining and mineralized nodule formation.
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without PRELP knockdown measured using microarray
We investigated the impact of PRELP knockdown on gene
expression proﬁle changes in MC3T3-E1 cells. As seen in Fig. 3A,
PRELP knockdown dramatically changed the expression proﬁle of
MC3T3-E1 cells. We then in silico analyzed the correlations of
differently expressed genes between PRELP-infected and PRELP-
mock by using the STRING database tool. The result revealed that
the b-catenin encoding gene Ctnnb1 served as a centered hub gene
within this PRELP-related gene network (Fig. 3B). These ﬁndings
suggested that PRELP may affect osteoblast differentiation through
b-catenin pathway.3.4. The effect of PRELP on b-catenin/connexin43 pathway
Furtherly we validated that PRELP knockdown couldsigniﬁcantly lower the total expression and nuclear translocation of
b-catenin in MC3T3-E1 cells (Fig. 4AeC). Considering the fact that
b-catenin can regulate connexin 43 (Cx43) at the level of gene
transcription, an important factor for the differentiation of osteo-
blasts, we investigated the effect of PRELP on Cx43 expression and
found that PRELP knockdown inhibited the Cx43 expression in both
mRNA and protein levels (Fig. 4DeE). These results indicated that
PRELP may participate in osteogenesis through b-catenin/con-
nexin43 pathway.4. Discussion
Elucidating the mechanisms responsible for bone hemostasis
has signiﬁcant implications in the prevention and treatment of
metabolic bone diseases such as osteoporosis. Current evidences
suggested that PRELP may be critical for osteoblast and bone he-
mostasis. Studies from other researchers had shown that PRELP
Fig. 3. Microarray analysis of PRELP knockdown on the expression proﬁles of MC3T3-E1 cells. (A) Differently expressed genes between PRELP shRNA and control groups; (B) b-
catenin encoding gene Ctnnb1 serves as centered hub genes within this PRELP-related gene network.
Fig. 4. Effect of PRELP knockdown on b-catenin/connexin43 signaling. PRELP knockdown can signiﬁcantly lower the total expression and nuclear location of b-catenin in MC3T3-E2
cells (AeC); PRELP knockdown inhibited the Cx43 expression in both mRNA and protein levels (DeE).
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through the molecular mechanisms involving nuclear trans-
location, interaction with p65 nuclear factor kappa B (NF-kB) and
inhibition of NF-kB transcriptional activity and reduction of
osteoclast-speciﬁc gene expression [6].
The present work further demonstrated that PRELP also had an
effect on osteoblast differentiation. In speciﬁc, our results demon-
strated that PRELP knockdown not only decreased ALP activity (an
early marker of the osteoblastic phenotype), but also inhibited
mineralization (markers of terminal differentiation) of osteoblasts.
Mechanically, we demonstrated that PRELP had potential ability to
affect the activity of b-catenin signaling and its downstream targetgenes. In particular, PRELP seems to participate the regulation of a
key osteogenesis activator Cx43 in osteoblasts [10,11]. Therefore,
we proposed that the changes in b-catenin/Cx43 can at least partly
account for the promotion effect of PRELP on MC3T3-E1 osteoblast
differentiation.
In this study, we identiﬁed a close link between PRELP and b-
catenin pathway activation ﬁrstly. In the previous study, Rucci et al.
revealed that the N-terminal heparin binding domain (hbdPRELP)
of PRELP failed to affect calvarial osteoblasts differentiation [6].
Therefore, we suggested that the effect of PRELP on osteoblast
differentiation may depend on its total or C-terminal domain
structures according to our ﬁndings. However, the exact
H. Li et al. / Biochemical and Biophysical Research Communications 470 (2016) 558e562562mechanisms need to be clariﬁed further.
It has been demonstrated that PRELP had a pharmacological
relevance as an osteoclast antagonist [12,13]. Our results furtherly
suggested that PRELP may act as both an osteoclast antagonist and
an osteoblast activator to combat bone loss and breast cancer
metastases, with a potential translational impact.
In summary, our study provided experimental evidence that
PRELP was required for osteoblast differentiation, and this effect
was mediated mainly through b-catenin signaling pathway to
activate a key osteogenesis gene Cx43. PRELP may be a promising
new target for metabolic bone diseases.
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